↓ Skip to main content

Osteonecrosis of the jaw

Overview of attention for article published in Current Rheumatology Reports, May 2008
Altmetric Badge

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
17 Mendeley
Title
Osteonecrosis of the jaw
Published in
Current Rheumatology Reports, May 2008
DOI 10.1007/s11926-008-0018-5
Pubmed ID
Authors

Philip N. Sambrook, Peter Ebeling

Abstract

Bisphosphonates are effective therapy for osteoporosis, Paget's disease, and metastatic bone disease. Generally, the side effects of bisphosphonates are minimal. Recently, an uncommon adverse reaction affecting the maxilla or mandible, called osteonecrosis of the jaw, has been reported, especially in those patients receiving high doses of bisphosphonates in the oncology setting. Regarding doses used to treat osteoporosis, clinicians must keep the very small potential absolute risk of jaw osteonecrosis in perspective and consider it in relation to the demonstrated benefit of bisphosphonates. Still, in a very small number of patients taking bisphosphonates, intractable, painful, nonhealing exposed bone may occur following dental extractions or denture irritation.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 18%
Professor > Associate Professor 3 18%
Student > Postgraduate 2 12%
Student > Master 1 6%
Lecturer > Senior Lecturer 1 6%
Other 2 12%
Unknown 5 29%
Readers by discipline Count As %
Medicine and Dentistry 10 59%
Decision Sciences 1 6%
Veterinary Science and Veterinary Medicine 1 6%
Unknown 5 29%